I am a postdoctoral fellow in the lab of Arnold Kriegstein at the University of California, San Francisco (UCSF). I focus on applying single-cell genomics techniques to study the development of specific cell types of the human brain, as well as to understand how these cell types are affected in various diseases, especially autism. Before starting my work at UCSF, I did my PhD at the University of Miami focusing on genomic analysis of autism. I did my B.S. and MS at Moscow State University in my native Russia, where I worked on animal models of epilepsy and Alzheimer’s disease.
Dmitry Velmeshev
Postdoctoral Scholar
University of California, San Francisco
From this contributor
Single-cell analysis suggests brain signaling problems in autism
Recent advances in technology allow researchers to measure RNA that is contained within the nucleus of a single brain cell.
Single-cell analysis suggests brain signaling problems in autism
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.